Meeting
2024 ASCO Genitourinary Cancers Symposium
An observational multicenter French study on unanswered questions in patients with advanced renal cell carcinoma (aRCC) treated with cabozantinib: OCTOPUS.
Authors
Constance Thibault
Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France
Constance Thibault , Loic Mourey , David Pasquier , Jean-Christophe Bernhard , Marion Boissier , Valérie Perrot , Laurence Albiges
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 430)
DOI
10.1200/JCO.2024.42.4_suppl.430
Abstract #
430
Poster Bd #
H12
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Study of cabozantinib in second line under real-life setting in patients with advanced renal cell carcinoma (aRCC): Study design of a French retrospective, multicenter study (OCTOPUS).
First Author: Antoine Thiery-Vuillemin
Poster
2023 ASCO Genitourinary Cancers Symposium
Financial toxicity from first-line TKI plus IO therapies for advanced renal cell carcinoma.
First Author: David Joseph Benjamin
Poster
2020 Genitourinary Cancers Symposium
Treatment duration and response of advanced renal cell carcinoma (aRCC) patients (pts) who have completed first-line (1L) treatment (tx): Results from a cross-sectional real-world study.
First Author: Giovanni Zanotti
Poster
2019 ASCO Annual Meeting
Clinical and economic outcomes associated with sequential treatment in patients with advanced renal cell carcinoma (aRCC).
First Author: Meredith M. Regan